HcFocus ads

What are the pitfalls to watch out for when navigating the Breakthrough Devices Program? https://ow.ly/8A6N50ZOCI4

The new RAPID coverage program launched in April 2026 aims to improve regulatory alignment between the FDA and CMS https://ow.ly/yuka50ZvZQQ

Could the NOPAIN Act unlock new revenue opportunities for your pain management technology? Learn more about this law and how it works. https://ow.ly/JjGg50ZuaOG

Securing a Category III CPT code is often viewed as a milestone, but it can sometimes create unexpected reimbursement challenges. A worthwhile read on how payer policies are evolving and why market access strategy is critical before choosing the Category III pathway. https://ow.ly/Aouv50ZHWHx

The latest from HcFocus – the role of AI in prior authorizations and denials https://ow.ly/ktqo50Z9ee3

FDA approved. Payors said no. Now what? Biotech, medical device, and diagnostic companies often hit a wall after FDA clearance. HcFocus bridges the gap, executing your full market access strategy until your product is covered. ✅ Reimbursement strategy & execution ✅ Regulatory — 510k, De Novo, Breakthrough ✅ Medical Affairs & physician engagement ✅ Payer submissions & prior authorizations Book a Free Consultation